References
References
A
Ahlskog JE. Parkinson's disease: medical and surgical treatment. Neurol Clin 2001 Aug;19(3):579-605.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th Edition. Washington, DC: American Psychiatric Press 1994.
Andersohn F et al. Cardiac and noncardiac fibrotic reactions caused by ergot- and nonergot- derived dopamine agonists. Movement Disorders 2009; 24(1): 129-133.
B
Barone P et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol 2006; 253(5): 601-7.
Barone P et al. Pramipexole ameliorates depression in Parkinson's disease: A randomized double-blind vs placebo trial. Abstract S43.004 presented at AAN 61st Annual Meeting 2009, Seattle, USA.
Barone P et al. Depression and antidepressant use in Parkinson's disease: Results from the PRODEST-PD study. Poster P1122 presented at 11th Congress of EFNS 2007, Brussels.
Barone P et al. PRODEST – Depressive symptoms in Parkinson's disease: Patterns across scales. Poster P1.167 presented at XVII WFN World Congress on Parkinson's Disease and Related Disorders 2007, Amsterdam, The Netherlands.
Barone P et al. Design of a randomized, placebo-controlled trial of pramipexole in patients with Parkinson's disease and depressive symptoms. Poster 601 presented at MDS 12th International Congress of Parkinson's Disease and Movement Disorders 2008, Chicago, USA.
Barone P et al. Efficacy of Double-Blind, Placebo-Controlled Pramipexole Against Depression in Parkinson's Disease. Poster M0-248 presented at MDS 13th International Congress of Parkinson's Disease and Movement Disorders 2009, Paris, France.
Barone P et al. Change in depressive symptoms in a pramipexole trial for Parkinson's disease patients: relative contributions of direct effect on mood vs indirect effect on motor function. Poster P2540 presented at 13th EFNS Congress 2009, Florence, Italy.
Beck AT et al. The BDI-II Manual. The Psychological Corporation 1996.
Borek LL, Amick MM, Friedman JH. Non-motor aspects of Parkinson's disease. CNS Spectr 2006; 11(7): 541-554.
Braak H et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
Braak H et al. Stages in the development of Parkinson's disease related pathology. Cell Tissue Res 2004; 318: 121-134.
Byrne R, Chaudhuri KR. Depression: a key non-motor symptom of Parkinson's disease. Prog Neurol Psychiatry 2006; 10(5):15-21.
C
Caap-Ahlgren M et al. Factors of importance to the caregiver burden experienced by family caregivers of Parkinson's disease patients. Aging Clin Exp Res 2002; 14(5): 371-377.
Chaudhuri KR, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 5(3): 235-245.
Chaudhuri KR et al. International multicenter pilot study of the first comprehensive self-completed non-motor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006; 21(7): 916–923.
Chaudhuri KR et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov Disord 2007 Oct 15; 22(13): 1901-1.
Clarke CE et al. Pramipexole for levodopa-induced complications in Parkinson's disease (Review). Cochrane Database of Systematic Reviews 2006; 3: 1-19.
Corbin A et al. Maintained pramipexole monotherapy treatment results in significantly lower dyskinesia rates in early Parkinson's disease: A result of the CALM-PD study after 4 years. Poster Presentation P-04 / 2.231 11 December 2007 XVII WFN World Congress of Parkinson's Disease and Related Disorders.
D
de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006; 5: 525-35.
F
Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann NY Acad Sci 2003; 991: 1-14.
Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease, Vol 2. Florham Park, NJ. Macmillan Health Care Information 1987; 153-163: 293-304.
G
Gelb DJ et al. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56(1): 33-39.
Goldberg JF et al. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004 Mar; 161(3): 564-6.
Grosset D et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord 2009 Apr 30;24(6):826-32.
H
Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62.
Hauser R et al. Double-blind evaluation of pramipexole extended-release (ER) in early Parkinson's disease. Abstract S43.003 presented at AAN 61st Annual Meeting 2009, Seattle, USA.
Hirsch E et al. Melanised dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988; 334: 345-348.
Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-442.
Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 1987; 45: 19-34.
Horstink M et al. Review of the therapeutic management of Parkinson's disease. Eur J Neurol 2006; 13: 1170-1202.
Houben J et al. Pramipexole improves depressive and motivational symptoms in Parkinson's disease. Abstract P575 presented at MDS 2006; Kyoto, Japan.
J
Jennings DL, Tabamo RT, Seibyl JS, Marek KM. InSPECT: Investigating the effect of short-term treatment with pramipexole or levodopa on [123I]ß-CIT and SPECT imaging. Abstract 465 at 11th International Congress of Parkinson's Disease and Movement Disorders, Istanbul 2007.
K
Koller WC. When does Parkinson's disease begin? Neurology 1992; 42(Suppl 4): 27-31.
Künig G et al. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease. Clin Neuropharm 1999; 22: 301-305.
Kuopio AM et al. The quality of life in Parkinson's disease. Mov Disord 2000; 15(2): 216-23.
L
Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004; 3: 309-316.
Leentjens A et al. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. Clin Ther 2009 Jan;31(1):89-98.
Lemke MR. Depressive symptoms in Parkinson's disease. Eur J Neurol 2008 Apr; 15 Suppl 1:21-5.
Lemke MR et al. Depression and Parkinson's disease. J Neurol 2004 Sep;251 Suppl 6:VI/24-7.
Lemke MR et al. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci 2005 Spring; 17(2): 214-20.
M
Maj J et al. The effect of repeated treatment with pramipexole on the central dopamine D3 system. J Neural Trans 2000; 107(12): 1369-1379.
Marsh L et al. Neuropsychiatric aspects of Parkinson's disease. Psychosomatics 2000; 41(1): 15-23.
Millan MJ et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002; 303(2): 791-804.
Miyasaki JM et al. Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review. Neurology 2002; 58: 11-17.
Möller JC et al. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord 2005 May; 20(5): 602-10.
N
National Institute for Health and Clinical Excellence. Parkinson's disease: diagnosis and management in primary and secondary care. NICE 2006. Last accessed: August 2009. (http://guidance.nice.org.uk/CG35).
Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003; 348: 1356-64.
Nutt JG, Wooten GF. Diagnosis and initial management of Parkinson's disease. New Engl J Med 2005; 353: 1021-7.
P
Parkinson Study Group, Holloway RG et al. Pramipexole vs levodopa as initial treatment for Parkinson's disease. Arch Neurol 2004; 61(7): 1044-1053.
Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. JAMA 2000: 284:1931-38.
Parkinsons Study Group CALM Cohort Investigators. Long-term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease. Arch Neurol 2009;66(5): 563-570.
Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287(13): 1653-1661.
Piercey MF. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol 1998; 21(3): 141-151.
Poewe W. Depression in Parkinson's disease. J Neurol 2007; 254(Suppl 5):49-55.
Poewe W et al. 33-week non-inferiority of extended- vs immediate-release pramipexole tablets in treatment of early Parkinson's disease. Abstract SC202 presented at 13th EFNS Congress 2009, Florence, Italy.
Poewe W et al. Pramipexole Extended-Release is Effective in Early Parkinson's Disease. Mov Disord Vol. 24, Suppl. 1, 2009: S1-S653.
Poewe W et al. Clinical efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease (CLEOPATRA-PD). Lancet Neurol 2007; 6(6): 513-520.
Pogarell O et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 2002; 72: 713-720.
Pramipexole European SPC. Annex I: Summary of product characteristics. URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Sifrol/H-133-PI-en.pdf. Date accessed October 2009.
R
Rabey JM et al. Evaluation of the Short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials. Clin Neuropharmacol 1997; 20(4): 322-337.
Rascol O et al. Dosage, safety, and tolerability for overnight switching from immediate- to extended-release pramipexole in early Parkinson's disease. Abstract SC205 presented at 13th EFNS Congress 2009, Florence, Italy.
Rascol O et al. Easy switching from immediate- to extended-release pramipexole in early Parkinson's disease at the same daily dosage. Poster TH-255 presented at Movement Disorders Society's 13th International Congress of Parkinson's Disease and Movement Disorders 2009, Paris, France.
Rektorova I et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10(4): 399-406.
Rektorova I et al. Cognitive performance in people with Parkinson's disease and mild or moderate depression: effects of dopamine agonists in an add-on to L-dopa therapy. Eur J Neurol 2005; 12: 9-15.
Reichmann H et al. Pramipexole in routine clinical practice. CNS Drugs 2003; 17(13): 965-973.
Riederer P, Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 1976; 38, 277-301.
S
Salin L et al. Double-blind evaluation of maintenance of efficacy of pramipexole extended-release in early Parkinson's disease. Abstract P06.150 presented at AAN 61st Annual Meeting 2009, Seattle, USA.
Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet 2004; 363: 1783-1794.
Schapira A et al. Decrease in off-time for extended- and for immediate-release pramipexole in advanced Parkinson's disease. Abstract SC203 presented at 13th EFNS Congress 2009, Florence, Italy.
Schapira AHV et al. Treatment options in the modern management of Parkinson disease. Arch Neurol 2007; 64(8): 1083-1088.
Schapira A et al. Efficacy and safety of pramipexole extended-release for advanced Parkinson's disease. Mov Disord Vol. 24, Suppl. 1, 2009: S1-S653.
Schapira A et al. PROUD: The impact of early vs. delayed treatment with pramipexole on new onset Parkinson's disease. Poster P1366 presented at the 12th EFNS Congress 2008, Madrid, Spain.
Seibyl J et al. Jennings D, Tabamo R, Marek K. The role of neuroimaging in the early diagnosis and evaluation of Parkinson's disease. Minerva Med 2005; 96(5): 353-364.
Snaith RP et al. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry 1995; 167(4): 551.
T
Tandberg E et al. The occurrence of depression in Parkinson's disease. Arch Neurol 1996; 53(2): 175-179.
Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol 2006; 5: 75-86.
V
Van Den Eeden SK et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003; 157: 1015-22.
W
Ward CD, Gibb WR. Research diagnostic criteria for Parkinson's disease. Adv Neurol 1990; 53: 245-249.
Z
Zhang ZX et al. Worldwide occurrence of Parkinson's disease: An updated review. Neuroepidemiology 1993; 12: 195–208.
Ziemssen T, Reichmann H. Non-motor dysfunction in Parkinson's disease. Parkinsonism Relat Disord 2007; 13(6): 323-332.
Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983; 67: 361-70.